CLPT · ClearPoint Neuro
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $11.48
Note written ·
Price against the kill line
26.1% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $11.48, on record since 11 November 2026. The shares are down 45.3% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $11.48, which sits above the 50-day average of closes and would show the shares recovering and leading the S&P 500. Full-year 2026 revenue above the $50.0 million top of the company's guide would also show the shares leading.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 28 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 12.1
- Revenue, change on a year (%)
- +36.3
- Gross margin (%)
- 58.5
- Operating margin (%)
- −52.4
- Free cash flow, four quarters ($M)
- −48.2
- Net cash, cash less debt ($M)
- −4.7
- Enterprise value to sales (×)
- 6.1
- Free-cash-flow yield (%)
- −17.7
All filed numbers
What ClearPoint Neuro reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 12.1 | +36.3 | 58.5 | −52.4 |
| first filed | 10.9 | +18.1 | 61.7 | −94.2 |
| first filed | 12.1 | +42.9 | 64.0 | −69.9 |
| first filed | 10.4 | +34.0 | 61.5 | −67.7 |
| first filed | 8.9 | +9.1 | 63.2 | −59.5 |
| first filed | 9.2 | +17.3 | 60.3 | −61.6 |
| Pre-tax income ($M) | −7.5 |
| Net income ($M) four quarters: −36.1 | −7.5 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +9.0 |
| Operating cash flow ($M) | −47.2 |
| Capital spending ($M) | 1.0 |
| Free cash flow ($M) | −48.2 |
| Cash and short-term investments ($M) | 46.2 |
| Debt ($M) long-term debt | 50.8 |
| Net cash, cash less debt ($M) | −4.7 |
| Deferred revenue ($M) −20.5% on a year | 2.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 8.0 |
| Inventory ($M) | 9.8 |
| Shareholders' equity ($M) | 27.3 |
| Market value ($M) | 272 |
| Enterprise value, market value plus net debt ($M) | 277 |
| Enterprise value to sales (×) | 6.1 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 10.0 |
| Free-cash-flow yield (%) | −17.7 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 14.4% of shares outstanding sold short, 6.6 days of average trading to cover, −2.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $2.5M |
The thesis
ClearPoint Neuro is more likely to lag the S&P 500 over the next three months. Its shares trade on the fate of uniQure's Huntington's disease gene therapy, which relies on ClearPoint's brain-delivery system, and ClearPoint's own 2026 revenue guidance has been cut twice. The fourth-quarter and full-year report, estimated for 25 February 2027, and the FDA's 1 May 2027 target date for uniQure's application settle the call.
The partner news has been good on paper. uniQure said on 2 November 2026 that the FDA accepted its AMT-130 application and granted priority review. The shares did not respond: they closed at $8.49 on 12 November 2026, the lowest close in 52 weeks, 56.7% below the 52-week intraday high of $19.63 set on 29 June 2026. The three-month change is –44.7%, from a close of $15.34 on 14 August 2026.
Revenue guidance for 2026 was narrowed to $48.0–50.0 million on 28 October 2026, from $48–52 million, so the top of the range was removed.
Bullish and bearish views on ClearPoint Neuro, Inc.
The bull case on ClearPoint Neuro, Inc. (CLPT), in brief: the FDA accepted the partner's application. uniQure announced on 2 November 2026 that the FDA accepted the AMT-130 biologics license application and granted priority review, with a target action date of 1 May 2027 (uniQure release, reported by NeurologyLive and BioPharm… The bear case: guidance keeps coming down.
Bull case
- The FDA accepted the partner's application. uniQure announced on 2 November 2026 that the FDA accepted the AMT-130 biologics license application and granted priority review, with a target action date of 1 May 2027 (uniQure release, reported by NeurologyLive and BioPharm International).
- Cash rose through the third quarter. Cash and equivalents were $46.2 million at 30 September 2026, against $29.4 million at 30 June 2026, after $22.0 million of net proceeds from the at-the-market equity program (ClearPoint third-quarter 2026 results, 28 October 2026).
- Delivery revenue returned to growth. Biologics and drug delivery revenue rose 11% to $4.9 million from $4.4 million a year earlier, reversing the 15% decline of the second quarter (28 October 2026 release).
- Core neurosurgery lines are growing. Neurosurgery navigation and therapy revenue rose 59% to $5.4 million, and capital equipment and software rose 68% to $1.7 million. Total revenue was $12.1 million, up 36% from $8.9 million (28 October 2026 release).
- Operating costs fell from the second quarter. Operating expenses were $13.4 million in the third quarter, down from $17.0 million in the second, and the net loss was $7.5 million, or $0.24 per share (28 October 2026 release).
Bear case
- Guidance keeps coming down. The 2026 revenue range was cut to $48–52 million on 3 August 2026 and narrowed to $48.0–50.0 million on 28 October 2026. Reaching the range needs a fourth quarter above the $12.1 million reported for the third.
- Margins fell. Gross margin was 58% against 63% a year earlier; the company cited overhead at the new laboratory facility and higher amortization of acquired intangibles (28 October 2026 release). The release also flags a risk that the laboratory may not reach Good Laboratory Practice compliance on the expected timeline.
- Growth leans on an acquisition. The 59% rise in neurosurgery navigation and therapy came mainly from IRRAflow products acquired with IRRAS in the fourth quarter of 2025, so the year-over-year comparison is not organic.
- Losses are funded by issuing shares. The $22.0 million raised at the market in the third quarter adds to the share count while the price falls. Operating cash burn was $20.1 million over the first nine months of 2026 (28 October 2026 results).
- The partner's latest data are weaker. uniQure's four-year data on 29 September 2026 showed 44% slowing on the composite Huntington's scale against an external control, not statistically significant, and uniQure shares fell about 40% that day (BioPharma Dive). The application rests on three-year data, and the FDA plans an advisory committee meeting whose date has not been announced (BioPharm International, 2 November 2026).
- Analyst targets are falling. Stifel kept a Buy rating but lowered its price target to $18, in a note reported on 30 October 2026.
Price setup
The shares closed at $8.49 on 12 November 2026, down from $9.17 on 11 November 2026 and below every close in the prior week: $8.69 on 5 November 2026, $8.60 on 6 November 2026, $9.17 on 9 November 2026 and $8.77 on 10 November 2026. That is a new 52-week closing low.
The 50-day average of closes is $11.37 and the 200-day average is $12.73, both well above the price. The downtrend has no recovery level close by.
SEC Form 4 filings show small insider activity. Directors Timothy Richards and John Fletcher received share grants of 319 and 993 shares at $12.21 on 1 October 2026. CEO Joseph Burnett exercised options on 12,517 shares at $3.47 on 2 September 2026. No open-market insider purchases appear in the recent filings.
Share supply is the visible overhang. The company runs an at-the-market program and has an S-3 registration statement on file. A resale prospectus effective 14 January 2026 covers up to 1,312,570 shares issued to former IRRAS holders.
Catalysts ahead
- 31 December 2026: Deadline to draw the Oberland note tranches of $25 million and $50 million. A drawdown or a further equity raise would show how the company funds losses after the third-quarter cash rise to $46.2 million.
- ~25 February 2027 (est.): Fourth-quarter and full-year 2026 results. Tests whether revenue reaches the $48.0–50.0 million guide, which needs a step-up from the $12.1 million third quarter, and sets the 2027 outlook.
- 1 May 2027: FDA target action date for uniQure's AMT-130 application under priority review. An approval opens a commercial use of ClearPoint's delivery system; a rejection breaks the partner path.
What would change the view
A daily close above $11.48, which sits above the 50-day average of closes and would show the shares recovering and leading the S&P 500. Full-year 2026 revenue above the $50.0 million top of the company's guide would also show the shares leading.
What it trades with
ClearPoint trades as a delivery proxy for uniQure: AMT-130 regulatory and data headlines have moved the shares more than ClearPoint's own reported numbers. uniQure's 29 September 2026 data release and the 2 November 2026 application acceptance are the two dated examples. Other small-cap neurosurgery device makers share the sector's sensitivity to equity funding, but no specific peer relationship is established here.
The evidence, claim by claim (8)
- FDA accepted uniQure's AMT-130 biologics license application with priority review; target action date 1 May 2027; an advisory committee meeting is planned. uniQure release 2 November 2026, via NeurologyLive and BioPharm International · as of
- Third-quarter 2026 revenue $12.1 million, up 36% from $8.9 million; biologics and drug delivery $4.9 million (up 11%); neurosurgery navigation and therapy $5.4 million (up 59%); capital equipment and software $1.7 million (up 68%). ClearPoint Neuro third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Third-quarter net loss $7.5 million ($0.24 per share); operating expenses $13.4 million; gross margin 58% versus 63% a year earlier. ClearPoint Neuro third-quarter 2026 results release (8-K exhibit 99.1) · as of
- Cash and equivalents $46.2 million at 30 September 2026, after $22.0 million of net at-the-market proceeds in the quarter, versus $29.4 million at 30 June 2026. ClearPoint Neuro third-quarter 2026 results release · as of
- 2026 revenue guidance narrowed to $48.0–50.0 million from $48–52 million. ClearPoint Neuro third-quarter 2026 results release · as of
- Stifel kept a Buy rating and lowered its price target to $18. Stifel analyst action reported 30 October 2026 · as of
- uniQure four-year AMT-130 data showed 44% slowing on the composite Huntington's scale versus external control, not statistically significant; uniQure shares fell about 40% that day. BioPharma Dive; uniQure press release 29 September 2026 · as of
- CEO Joseph Burnett exercised options on 12,517 shares at $3.47. SEC Form 4 filed 3 September 2026 · as of
Sources
Related · shared themes
CYRX
CryoPort
Cryoport's cold-chain business for cell and gene therapies is growing faster and posted a second positive adjusted EBITDA quarter, with…
DHR
Danaher
Danaher's shares have a modest edge over the S&P 500 because mid-teens bioprocessing orders should reach revenue in 2027. Formal 2027…
ICLR
ICON
ICON plc's orders have recovered into fee-earning work, with a third-quarter direct-fee book-to-bill near 1.3, giving the shares a modest…
IQV
IQVIA Holdings
IQVIA's clinical-research bookings are outpacing revenue, with third-quarter 2026 bookings up 15% at a 1.2x book-to-bill and guidance…
See also · stocks to watch